Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pixuvri

- PMLiVE

Dept of Health to launch sepsis awareness campaign across UK

Aims to transform public understanding and NHS handling of the condition

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Bristol-Myers Squibb (BMS) building

NICE finalises record-breaking Opdivo/Yervoy appraisal

BMS’s immunotherapy combination receives recommendation in 24 days

Brextinction

Evolution predicts tragic consequences from the UK's choice

- PMLiVE

Celgene disappointed as Revlimid fails lymphoma trial

Study shows improvement in progression-free survival but no overall survival rate benefit

Roche Basel Switzerland

Roche’s Gazyvaro flunks trial in non-Hodgkin’s lymphoma

Failed to improve progression-free survival when compared with its MabThera/Rituxan therapy

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

EISAI

Eisai slams Cancer Drugs Fund ‘black hole’

Will consider legal action to address the ‘unfair and inequitable situation’ for UK cancer patients

- PMLiVE

EMA: ‘business as usual’ – for now – after Brexit

And says it will be up to remaining EU members to decide on its future location

- PMLiVE

Omnicom launches new DDB Health network

Will include its AgencyRx, Flashpoint, Synergy and DDB Health agencies

- PMLiVE

AZ, BMS and Boehringer among UK Prix Galien finalists

They join Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda

ABPI London offices

UK pharma HCP payment database goes live

Two-thirds of payments related to research and development work

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links